Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb Extension Study of Sonlicromanol in m.3243A>G Mitochondrial Disease
2020-000832-23Phase 2Completed
- Sponsor
- Khondrion
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sonlicromanol in Mitochondrial disease due to m.3243A>G mitochondrial DNA variant (m.3243A>G), mitochondrial encephalomyopathies and maternally inherited diabetes and deafness (MIDD), sponsored by Khondrion. Primary endpoint: Frequency of TEAEs throughout the treatment period. Started Jun 2020; status: completed.
02
Drugs
sonlicromanol
03
Conditions
Mitochondrial disease due to m.3243A>G mitochondrial DNA variant (m.3243A>G)mitochondrial encephalomyopathiesmaternally inherited diabetes and deafness (MIDD)
Beyond the preview
Go deeper on 2020-000832-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000832-23.